(EHP) Epistem Holdings
Summary
Buy UK shares for just £1.50. No hidden charges, admin or inactivity fees
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Headline | Source | |
|---|---|---|
|
|
||
| 10-01-12 | RNS |
|
|
RNS Number : 3113V Epistem Holdings plc 10 January 2012 Company Epistem Plc TIDM EHP.L (AIM) Headline Directors' Shareholdings Released 10th January 2012 Number
Epistem Holdings Plc ("Epistem" or the "Company")
Directors' Shareholdings & AGM
Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009
As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors each increased their beneficial interests in the Company by 297 ordinary shares of 1.5p each. These shares were acquired on 2 November 2011, 9 November 2011 and 23 December 2011 at prices of 383p, 383pand 358p respectively.
Following these transactions, the current beneficial interests of the executive Directors are set out below:
Matthew Walls 8,965 (0.10%) Dr Catherine Booth 983,320 (11.12%) Dr Jeffrey Moore 15,645 (0.18%) John Rylands 193,218 (2.18%)
Epistem further announces that all resolutions proposed at the Annual General Meeting held on 14 December 2011 were passed.
For further details please contact:
Epistem Plc Matthew Walls, CEO +44 161 606 7258 John Rylands, Finance Director +44 161 606 7244
Peel Hunt LLP James Steel / Vijay Barathan +44 20 7418 8900
This information is provided by RNS The company news service from the London Stock Exchange More |
||
| 19-12-11 | RNS |
|
|
RNS Number : 2850U Epistem Holdings plc 19 December 2011
Epistem Holdings Plc ("Epistem" or the "Company") Directors' shareholdings and issue of equity Epistem (AIM: EHP), the biotechnology and personalised medicine company, today announces the following transactions by two of its Directors and the application for 117,000 new ordinary shares of £0.015 each to be admitted to trading on AIM. On 19 December 2011, Jeffrey Moore, Managing Director Novel Therapies, exercised options over 29,000 ordinary shares at an exercise price of 120p per share. On the same day, Jeffrey Moore disposed of 29,000 ordinary shares at a price of 350p per share. Following these transactions, Jeffrey Moore has a beneficial interest in 15,348 ordinary shares (0.17%) and also has options granted but not yet exercised over a total of 320,999 ordinary shares. On 19 December 2011, Robert Nolan, a non-executive Director, sold 3,000 ordinary shares at a price of 350p per share. Following this disposal Robert Nolan has a beneficial interest in 5,065 ordinary shares (0.06%) and also has options granted but not yet exercised over a total of 93,528 ordinary shares. Application has been made for 117,000 new ordinary shares of £0.015 each to be admitted to trading on AIM. The application has been made in respect of options exercised under the terms of the 2007 Epistem EMI scheme. Admission in respect of 117,000 new ordinary shares is expected to be effective on 23 December 2011 and, when issued, the 117,000 new ordinary shares will rank pari passu in all respects with the Company's existing ordinary shares. Following admission of the 117,000 new ordinary shares, Epistem will have 8,844,381 ordinary shares of £0.015 in issue. For further details please contact: Epistem Plc Matthew Walls: Chief Executive Officer +44 (0) 161 606 7258 John Rylands: Finance Director Peel Hunt LLP James Steel +44 (0) 20 7418 8900 Vijay Barathan
This information is provided by RNS The company news service from the London Stock Exchange More |
||
| 25-11-11 | RNS |
|
|
RNS Number : 8020S Epistem Holdings plc 25 November 2011
Epistem Holdings Plc 25 November 2011
Epistem Holdings Plc ("Epistem" or the "Company") £2.8 million Cash Placing
Epistem (AIM: EHP), the biotechnology and personalised medicine company, is pleased to announce that it has agreed to raise approximately £2.8 million before expenses through a placing for cash of 793,398 new ordinary shares of 1.5 pence each with a range of existing and new institutional investors.
The new ordinary shares, which represent 10.0 per cent of Epistem's issued share capital prior to the placing, have been conditionally placed at a price of 350 pence per share on Thursday 24th November and Friday 25th November. This placing price represents a 3.4% discount to the closing middle market price on 24 November 2011.
The Company will use the net proceeds of the placing which are expected to be some £2.7 million to accelerate the development and commercialisation of its Genedrive™ molecular diagnostic device. Epistem has developed Genedrive™, a handheld 'Point of Care' device for molecular diagnostics, across a broad range of infectious disease as well as for use as a companion diagnostic for pharmacogenomics, bio-defense and forensics applications. Genedrive™ is expected to provide a significant technological advance and new cost effective approach to the rapid diagnosis of bacterial, viral, fungal and gene mutations. Epistem continues to build on its scientific and technical strengths as it transforms into a diverse, technology-leading biotechnology and personalised medicine group.
Application will be made to the London Stock Exchange for the new ordinary shares to be admitted to trading on AIM. Admission in respect of 71,490 new ordinary shares is expected to be effective on 1 December 2011 and in respect of the remaining new ordinary shares on 2 December 2011. When issued, the new ordinary shares will rank pari passu in all respects with the Company's existing ordinary shares. Following completion of the placing, Epistem will have 8,727,381 ordinary shares of 1.5 pence each in issue.
For further details please contact:
Epistem Plc Matthew Walls: Chief Executive Officer +44 (0) 161 606 7258 John Rylands: Finance Director
Peel Hunt LLP James Steel +44 (0)207 418 8900 Vijay Barathan
De Facto Financial Mike Wort +44 (0)207 556 1064 Anna Dunphy
Notes to Editors: Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and pharmacogenomics in the areas of oncology, gastrointestinal, dermatological and infectious disease. Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.
This information is provided by RNS The company news service from the London Stock Exchange More |
||
| 09-11-11 | RNS |
|
|
RNS Number : 7374R Epistem Holdings plc 09 November 2011
Epistem Holdings Plc ("Epistem" or "the Company") 2011 Annual Report and Accounts & Notice of AGM Epistem confirms that it has published its Annual Report and Accounts for the year ended 30 June 2011. The document is available from the Company's website: www.epistem.co.uk. Epistem confirms that its 2011 Annual General Meeting will be held at 11.00am on Wednesday, 14th December 2011 at 48 Grafton Street, Manchester. The AGM Notice will be posted to shareholders on 22nd November 2011. For further information contact: Epistem Holdings Plc Matthew Walls, Chief Executive Officer ++44 161 606 7258 John Rylands, Finance Director ++44 161 606 7244 Peel Hunt LLP Nominated Adviser: James Steel/Vijay Barathan ++44 207 418 8900
Notes for editors Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and pharmacogenomics in the areas of oncology, gastrointestinal, dermatological and infectious disease.
Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem has developed a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.
This information is provided by RNS The company news service from the London Stock Exchange More |
||
| Result Pages: 1 | ||||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| 07-01-12 | ||||
|
|
||||
|
|
||||
| 06-01-12 | ||||
|
|
||||
|
|
||||
|
Rockhopper Exploration, ReNeuron, Epistem, Kefi Minerals and Wolf Minerals
Broker Round January 06. at 3:29 pm http://bit.ly/A3QfU0 |
||||
| 06-01-12 | ||||
|
|
||||
|
|
||||
|
ImmuPharma, Shire, ReNeuron and Epistem make it into Merchant's top 12 for 2012
11:12 am by Ian Lyall http://bit.ly/yRX76l |
||||
| 29-12-11 | ||||
|
|
||||
|
|
||||
|
http://www.theshedend.com/topic/19000-a-tragic-tale-of-a-harlequins-rugby-hope-jack-brennan/
Epetheloid Sarcoma..the type that Jack Brennan is suffering from, is currently being treated with 'new' experimental drugs in conjunction with chemo therapy at the Royal Marsden under the care of Prof. Ian Juddson, Britain's foremost oncologist in this sphere. http://www.ecancermedicalscience.com/tv/most-viewed.asp?play=63&cid=0&scid=0&q= ValiRx's GeneICE technology has been developed for silencing rebellious genes, which cause conditions such as cancer and various neurological problems. The 'sarcomas' or soft tissue cancers could also be targeted by the drugs being developed by VALiRx Imperial College, University of London, has been working in collaboration with ValiRx and is currently carrying out the late pre-clinical development of ValiRx's lead therapeutic, VAL101 with funding awarded from the Eurostars scheme. The company announced that stability and toxicology studies are currently underway. The production of the VAL101 compound is going to plan and has been optimised and simplified, which by extension makes the compound cheaper to produce, thereby adding future value. More on this innovative bio-pharma company.... Hybridan raises target price 3-fold to... 1.66p ! http://www.proactiveinvestors.co.uk/companies/news/37128/ValiRx%20has%20its%20price%20target%20increased%20by%20broker%20Hybridan proactive news/articles: Everyone a 'positive' update http://www.proactiveinvestors.co.uk/LON:VAL/ValiRx/ Video-interview-unlimited potential of GeneICE http://www.proactiveinvestors.co.uk/companies/stocktube/760/satu-vainikka-from-valirx-talks-about-the-unlimited-potential-of-geneice-.html |
||||
|
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
Markets: FTSE 100 uncertain on TuesdayEditor's Pick:
George Godber’s AIM stock picksEditor's Pick:
How to pay less tax on your investmentsEditor's Pick:
Hybridan's Small Cap WrapEditor's Pick:
View from the top: Ortac Resources interview

